INTRACELLULAR DELIVERY AND MITOCHONDRIAL TARGETING BY FLUORINATION

    公开(公告)号:US20220152226A1

    公开(公告)日:2022-05-19

    申请号:US17437417

    申请日:2020-03-27

    发明人: Lin Zhu Yin Liu Ying Tu

    摘要: In an embodiment, the present disclosure relates to a targeting platform that includes a targeted delivery system including an agent. In some embodiments, the targeted delivery system is modified by fluorination. In some embodiments, the targeted delivery system is electrically charge neutral. In a further embodiment, the present disclosure relates to a method that includes fluorinating a targeting compound with a fluorinating reagent and loading an agent with the fluorinated targeting compound to thereby form a micelle. In an additional embodiment, the present disclosure relates to a targeting platform that includes a fluorinated polymeric system including an agent. In another embodiment, the present disclosure relates to a method that includes fluorinating a targeting compound with a fluorinating reagent and loading an agent with the fluorinated targeting compound to thereby form a micelle. Additionally, the method can include administering the fluorinated targeting compound to a subject.

    CONFIGURABLE BNN ASIC USING A NETWORK OF PROGRAMMABLE THRESHOLD LOGIC STANDARD CELLS

    公开(公告)号:US20220121915A1

    公开(公告)日:2022-04-21

    申请号:US17504279

    申请日:2021-10-18

    IPC分类号: G06N3/063 G06N3/04

    摘要: A configurable binary neural network (BNN) application-specific integrated circuit (ASIC) using a network of programmable threshold logic standard cells is provided. A new architecture is presented for a BNN that uses an optimal schedule for executing the operations of an arbitrary BNN. This architecture, also referred to herein as TULIP, is designed with the goal of maximizing energy efficiency per classification. At the top-level, TULIP consists of a collection of unique processing elements (TULIP-PEs) that are organized in a single instruction, multiple data (SIMD) fashion. Each TULIP-PE consists of a small network of binary neurons, and a small amount of local memory per neuron. Novel algorithms are presented herein for mapping arbitrary nodes of a BNN onto the TULIP-PEs. Comparison results show that TULIP is consistently 3× more energy-efficient than conventional designs, without any penalty in performance, area, or accuracy.

    ANGELMAN SYNDROME ANTISENSE TREATMENT

    公开(公告)号:US20220090075A1

    公开(公告)日:2022-03-24

    申请号:US17523456

    申请日:2021-11-10

    IPC分类号: C12N15/113 C07H21/04

    摘要: Disclosed herein are antisense oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA at the 5′-end of UBE3A-AS, which is downstream of SNORD115-45 snoRNA. Also disclosed are pharmaceutical compositions and methods for treatment of Angelman syndrome.

    AUTONOMOUS LANDING SYSTEMS AND METHODS FOR VERTICAL LANDING AIRCRAFT

    公开(公告)号:US20220017235A1

    公开(公告)日:2022-01-20

    申请号:US17180326

    申请日:2021-02-19

    摘要: An autonomous landing system for vertical landing aircraft includes a vertical landing aircraft including a powertrain and an onboard camera, a motion-stabilized visual cue including a visual indicator, wherein the visual cue is configured to maintain a fixed orientation of the visual indicator with respect to a horizon, and an autonomous control system configured to control a position of the aircraft with respect to the visual indicator of the visual cue based on image data captured by the onboard camera.

    Modified lantibiotics and methods of making and using the modified lantibiotics

    公开(公告)号:US11225510B2

    公开(公告)日:2022-01-18

    申请号:US16806641

    申请日:2020-03-02

    摘要: The subject invention pertains to a modified lantibiotic containing an intact cysteine at the C-terminus, particularly, a cysteine that is not decarboxylated and that contains a free carboxyl group. Derivatives of the modified lantibiotic comprising a moiety conjugated to the carboxyl group of the terminal cysteine are also provided. A bacterium that produces a modified lantibiotic having an intact cysteine at the C-terminus are also provided, wherein the bacterium is genetically modified to inactivate a gene that encodes a decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic. Methods of producing a modified lantibiotic having an intact cysteine at the C-terminus by culturing a bacterium that synthesizes the modified lantibiotic and purifying the lantibiotic are also provided. Mutants of lantibiotics, particularly, mutacin 1140 having higher anti-bacterial activity or higher bacterial expression compared to mutacin 1140 are also provided.